If the negative safety data that was covered up by GSK comes to light.
Otherwise it goes to adcom where it will be voted down.
Every time the short-dude has gone I to panic mode, the stock rose nicely.
He is like the rooster that makes a bunch of noise before the sun rises. So yes, the guy is a #$%$.
The EMA will correct their course. Mark this post. It will take time (1-year+) but in the end, Eteplirsen will stand alone in Europe approved, and Drisapersen will be stuck without approval, arguing and appealing but left out in the cold.
Nah, don't short BMRN. Lots of good drugs in the pipeline, just Drisapersen isn't one of them. Vosoritide is a keeper. If a drug company got a base-hit with 50% of the drugs they developed, they would be at the hall of fame level.
I'm not surprised the BMRN CEO didn't mention the safety issues with Drisapersen in the interview today. I'm trying to understand if BMRN knew of the negative safety data or not.
He deletes them as he goes. Don't worry though. He didn't really short any. They don't let guys at the insane asylum have broker accounts. Though they do let them have multiple aliases to match the multiple personalities.
As their panic level goes up, so does the stock price.
They will get 100% of the market share with NO competition.
I'd take the IV port.
Read it over on the SRPT board. That GSK covered up negative safety data from the clinical trials on Drisapersen. Don't know to what extent BMRN is involved if any. Since BMRN had the lead in Drisapersen I would have to think they knew before GSK would.
BMRN announced successful Phase 2 results for vosoritide to combat dwarfism. I guess they will probably abandon Drisapersen and cut their losses. Vosoritide looks like it might be safe and might actually work.
I know, right? Any fool can post up/down anything. It doesn't make it so.
Prepare for jump$.
Agreed that BMRN is a good company as well as investment. Even great athletes strike out once in a while. Drisapersen was a loss they will probably just walk away from like GSK did.
As effective as a placebo, but with toxicity issues. Doesn't get to be more of a failure than that. But by all means, if you want to go invest in it, put your money into BMRN.
Just makes no sense to be here arguing with us.